血清可溶性类似收费受体4和COVID-19患者临床严重性风险

Maha E Houssen1, Marwa O Elmaria2, Dina Badr3

  • 1Biochemistry Department Faculty of Pharmacy Damanhour University, Damanhour, 22511, Egypt. mahahoussen@yahoo.com.

Pneumonia (Nathan Qld.)
|January 4, 2024
PubMed
概括

在严重的COVID-19患者中,血清溶解的托尔样受体4 (sTLR4) 和溶解的CD14 (sCD14) 水平升高. 这些标记物显示出用于评估COVID-19临床严重性的诊断潜力.